1Wurm FM. Production of recombinant protein therapeutics in cultivated mammalian cells [J]. Nature Biotechnology, 2004, 22(11) : 1393-1398.
2Chung I, Deisseroth AB. Recombinant adenoviral vector containing tumor-specific L-plastin promoter fused to cyto- sine deaminase gene as a transcription unit: generation and functional test [J]. Archives of Pharmacal Research, 2004, 27(6) : 633-639.
3Fooks AR, Schadeck E, Liebert UG, et al. High-level expression of the measles virus nucleocapsid protein by using a replication-deficient adenovirus vector: induction of an MHC-l-restricted CTL response and protection in a murine model [J]. Virology, 1995, 210(2) :456-465.
4Garnier A, C6t J, Nadeau I, et al. Scale-up of the adenovirus expression system for the production of recombinant protein in human 293S cells[J]. Cytotechnology, 1994, 15(1-3):145-155.
5Wang P, Kan QC, Yu ZJ, Li L, Zhang ZX, Pan X. Construction and identification of a recombinant adenovirus vec- tor expressing His-tag-ICP47 fusion gene [J]. Life Science Journal, 2012, 9 (1) : 756-763.
6Douglas JT. Adenoviral vectors for gene therapy [J]. Molecular Biotechnology, 2007, 36(1): 71-80.
7Liu X, Gao Y, Luo B, et al. Construction and Antiapoptosis Activities of Recombinant Adenoviral Expression Vector Carrying EBV Latent Membrane Protein 2A[J]. Gastroenterology Research Practice, 2011, 2011(4): 1-1.
8Yin J, Zhang Y, Yang L, et al. Effective inhibition of specific gene by adenoassociated virus (AAV)-mediated ex- pression of small interfering RNA [J]. African Journal of Biotechnology, 2013, 10(15) : 2844-2849.
9Li R, Hu H, Ma H, et al. The anti- tumor effect and increased tregs infiltration mediated by rAAV-SLC vector [J]. Molecular Biology Reports,2013,40(10):5615-5623.
10Yu Y L, Wei C W, Chen Y L, et al. Immunotherapy of breast cancer by single delivery with rAAV2-mediated in- terleukin-15 expression[J]. International Journal of Oncology, 2010, 36(2):365-370.
